Nucana Plc (NCNA)
NASDAQ:NCNA
NCNA Stock Chart & Stats
$3.33
-$0.06(-4.88%)
At close: 4:00 PM EST
$3.33
-$0.06(-4.88%)
Day’s Range― - ―
52-Week Range$1.39 - $267.80
Previous CloseN/A
Volume88.96K
Average Volume (3M)174.33K
Market Cap
$5.83M
Enterprise Value-$17.12M
Total Cash (Recent Filing)$24.21M
Total Debt (Recent Filing)$674.81K
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-2.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit251.44
Enterprise Value/Ebitda0.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Platform ProgressNUC-7738’s encouraging Phase 2 activity in PD-1 inhibitor–resistant metastatic melanoma and the company’s pursuit of FDA guidance for a potential registrational path materially strengthens NuCana’s ProTide platform. Durable clinical proofpoints and a potential regulatory path increase the likelihood of eventual commercialization, support partner interest, and reduce binary trial risk relative to earlier discovery-stage peers.
Cash Runway Funded Through Key MilestonesA reported cash runway into 2029 after 2025 financings and warrant restructuring provides durable runway to complete enrollment, report pivotal/registrational data and pursue regulatory interactions. Extended liquidity reduces near-term financing pressure, allowing focus on clinical execution and strategic business development through multiple key value-inflection points.
Experienced R&D And Operations LeadershipAppointing an experienced oncology R&D operations leader strengthens program execution and regulatory readiness. Theresa Bruce’s 25+ years of clinical development experience supports trial management, registration planning and combination strategies, improving the company’s ability to translate clinical data into credible regulatory and commercial plans over the medium term.
Bears Say
Pre-revenue Business ModelNuCana’s pre-revenue status is a fundamental constraint: without product sales, the company cannot self-fund operations and must rely on external financing or partnerships. This structural dependence increases execution risk, creates milestone-driven valuation swings, and makes long-term sustainability contingent on successful clinical outcomes and commercialization.
Persistent Cash BurnDespite improvement in 2025 operating cash flow, ongoing negative operating and free cash flow indicates sustained burn. Continued reliance on external capital introduces dilution risk and execution vulnerability if financing markets tighten; variable free cash flow also complicates multi-year planning for trials and regulatory activities.
Equity Volatility And Dilution HistoryA history of sharp equity drawdowns and rebound implies prior dilutive financings or valuation compression, which can reduce incumbent shareholder value and signal recurring capital raises. This structural pattern raises the probability of future dilution to fund development and complicates investor confidence and long-term ownership economics.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $1.39 and its highest was $267.80 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $5.83M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is May 14, 2026 which is in 47 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Mar 19, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.509%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
8.30% Other Institutional Investors
91.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---